Replies to post #109218 on Biotech Values

[DewDiligence]

But patients enrolled in the trials couldn't have prior or current evidence of radiographically detectable bone metastasis, which is entirely different from EXEL184.

That’s true only for the Denosumab trial in http://clinicaltrials.gov/ct2/show/NCT00286091 ; it is not true for the Denosumab trials in http://clinicaltrials.gov/ct2/show/NCT00321620 , http://clinicaltrials.gov/ct2/show/NCT00321464 , and http://clinicaltrials.gov/ct2/show/NCT00330759 .

The definition of progression in metastatic prostate cancer incorporates bone-met progression.

You seem to be arguing that treating metastatic prostate cancer per se is somehow different from preventing and treating bone mets, which is like trying to thread a needle that doesn’t exist.